Antibacterials

The powerful broad-spectrum phage COP-01/20 cocktail was developed to treat multidrug-resistant Staphylococcus epidermidis infections. Careful COP-01/20 phage selection and purification process provide excellent efficiency and safety profile.

Name Target Stage development pre-clinical clinical trial
COP-01/20 multidrug-resistant S. epidermidis       development
  • Activity against multidrug-resistant S. epidermidis
  • Penetrating biofilms
  • Stability
  • Superior manufacturing process

COP-01/20 is a cocktail of stabilized bacteriophages for treatment of Staphylococcus epidermidis infections. S. epidermidis, the most abundant microbe of normal commensal flora of human skin and mucous membranes is the most common cause of primary bacteremia and infections of indwelling medical devices.
COP-01/20 has a broad host range and synergistic activity with antibiotics against S. epidermidis biofilms in vitro.

 

Contact: biotech@cobik.si

Pipeline

COBIK is aimed to address the most pressing health challenges of the 21st century: antibiotic resistance and emerging viral diseases. Our pipeline is focused on bacteriophage-based solutions and viral vaccines.

READ MORE

Services

COBIK provides development of challenging bioprocess workflows, non-GMP manufacturing capabilities and complete project management expertise.

READ MORE

References

COBIK is a reliable partner to biopharma industry, academia and innovation ecosystem. Our drive for excellence is exemplified in track record of industrial services, patents, scientific publications and collaborations.

READ MORE

Outreach

We are determined to give back to our local community. Through public outreach events COBIK promotes science to school children and sparks curiosity in people of all ages.

READ MORE
cobik

Centre of Excellence for Biosensors, Instrumentation and Process Control

Mirce 21

SI-5270 Ajdovščina

info@cobik.si

About